CoChat

The diagnosis and medical management of advanced neuroendocrine tumors.

The DOI matches its Crossref record; 657 of the 670 references it cites were found in a registry or an index.

Abstract

Neuroendocrine tumors (NETs) constitute a heterogeneous group of neoplasms that originate from endocrine glands such as the pituitary, the parathyroids, and the (neuroendocrine) adrenal, as well as endocrine islets within glandular tissue (thyroid or pancreatic) and cells dispersed between exocrine cells, such as endocrine cells of the digestive (gastroenteropancreatic) and respiratory tracts. Conventionally, NETs may present with a wide variety of functional or nonfunctional endocrine syndromes and may be familial and have other associated tumors. Assessment of specific or general tumor markers offers high sensitivity in establishing the diagnosis and can also have prognostic significance. Imaging modalities include endoscopic ultrasonography, computed tomography and magnetic resonance imaging, and particularly, scintigraphy with somatostatin analogs and metaiodobenzylguanidine. Successful treatment of disseminated NETs requires a multimodal approach; radical tumor surgery may be curative but is rarely possible. Well-differentiated and slow-growing gastroenteropancreatic tumors should be treated with somatostatin analogs or alpha-interferon, with chemotherapy being reserved for poorly differentiated and progressive tumors. Therapy with radionuclides may be used for tumors exhibiting uptake to a diagnostic scan, either after surgery to eradicate microscopic residual disease or later if conventional treatment or biotherapy fails. Maintenance of the quality of life should be a priority, particularly because patients with disseminated disease may experience prolonged survival.

Overview

Integrity signals

Registry

Crossref · 10.1210/er.2003-0014

Cites

657 of 657 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Items 601–657 of 657

Research works printed but not linked: 3

  1. Krenning, 1994, Essentials of peptide receptor scintigraphy with emphasis on the somatostatin analog octreotide., Semin Oncol, 21, 6
  2. Janson, 2000, Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors., J Nucl Med, 41, 1514
  3. Bartsch, 1990, Treatment of metastatic carcinoid tumors by recombinant human interferon-α. Results from a phase II study., J Cancer Res Clin Oncol, 116, 305

Cited by

See all 679

Metadata

Authors
Kaltsas, G. A., Besser, G. M., & Grossman, A. B.
Affiliations
St Bartholomew's Hospital (GB)
Venue
Endocrine Reviews
Published
2004-06-01
Volume
25
Issue
3
Pages
458-511
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
OpenAlex
W2031301095
Cited by
674
References
670
Citations by year
2026: 4 · 2025: 19 · 2024: 17 · 2023: 26 · 2022: 17 · 2021: 23 · 2020: 23 · 2019: 24 · 2018: 31 · 2017: 27 · 2016: 34 · 2015: 46 · 2014: 30 · 2013: 37 · 2012: 49
FWCI
4.65
Type
journal article
Language
en
Open access
closed
Locations
  • Endocrine Reviews (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
Keywords
neuroendocrine tumors, diagnosis, tumor markers, endocrine syndromes, somatostatin analogues, MIBG scintigraphy, endoscopic ultrasound, interferon-alpha, chemotherapy, radionuclide therapy, multimodal therapy, quality of life
MeSH terms
Adrenal Gland Neoplasms, Animals, Antineoplastic Combined Chemotherapy Protocols, Gastrointestinal Neoplasms, Humans, Pancreatic Neoplasms, Parathyroid Neoplasms, Pituitary Neoplasms, Prognosis, Quality of Life, Sensitivity and Specificity, Somatostatin, Thyroid Neoplasms, Tomography, X-Ray Computed, Biomarkers, Tumor, Interferon-alpha, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.